StreetInsider.com News Articles

Form 4 AMARIN CORP PLC\UK For: Jul 01 Filed by: Provoost Jonathan

Wed, 15 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260715/26774839.html

Form 4 AMARIN CORP PLC\UK For: Jul 01 Filed by: Provoost Jonathan

Wed, 15 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260715/26774839.html

Form 4 AMARIN CORP PLC\UK For: Jul 01 Filed by: Fishman Peter L.

Wed, 15 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260715/26774846.html

Form 4 AMARIN CORP PLC\UK For: Jul 01 Filed by: Fishman Peter L.

Wed, 15 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260715/26774846.html

Form 4 AMARIN CORP PLC\UK For: Jul 01 Filed by: Keenan David Paul

Wed, 15 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260715/26774849.html

Form 4 AMARIN CORP PLC\UK For: Jul 01 Filed by: Keenan David Paul

Wed, 15 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260715/26774849.html

Form 4 AMARIN CORP PLC\UK For: Jul 01 Filed by: Ketchum Steven B

Wed, 15 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260715/26774850.html

Form 4 AMARIN CORP PLC\UK For: Jul 01 Filed by: Ketchum Steven B

Wed, 15 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260715/26774850.html

Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026

Wed, 15 Jul 2026 08:00:00 -0400

DUBLIN, Ireland and BRIDGEWATER, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report second quarter 2026 financial results and conduct a conference call on Wednesday, July 29, 2026. The Company will issue a press release detailing its second quarter 2026 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET.

Information on how to participate is as follows.

Access to the live call:
Via telephone: Dial in

Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026

Wed, 15 Jul 2026 08:00:00 -0400

Information on how to participate is as follows.

Access to the live call:
Via telephone: Dial in

Form 4 AMARIN CORP PLC\UK For: Jun 26 Filed by: Berg Aaron

Tue, 30 Jun 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260630/26714870.html

Form 4 AMARIN CORP PLC\UK For: Jun 26 Filed by: Berg Aaron

Tue, 30 Jun 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260630/26714870.html

Amarin highlights Vascepa cost advantage over new injectable rivals

Tue, 30 Jun 2026 16:16:32 -0400

Amarin Corporation plc (NASDAQ: AMRN) issued a statement positioning its oral triglyceride drug Vascepa (icosapent ethyl) against recently FDA-approved injectable apolipoprotein C-III therapies for severe hypertriglyceridemia, defined as triglyceride levels at or above 500 mg/dL.

The company cited a significant price difference between Vascepa and the new injectable treatments. According to Amarin, the annual wholesale acquisition cost of Vascepa is approximately $4,200 per patient, compared to $40,000 per patient for the most recently approved injectable APOC3 therapy.

Amarin said Vascepa has been prescribed more than 30 million times globally and claims it is the first and only FDA-approved therapy shown to reduce

Amarin highlights Vascepa cost advantage over new injectable rivals

Tue, 30 Jun 2026 16:16:32 -0400

Amarin said Vascepa has been prescribed more than 30 million times globally and claims it is the first and only FDA-approved therapy shown to reduce

Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape

Tue, 30 Jun 2026 16:15:00 -0400

Clinically Validated, Increasingly Prescribed, Widely Reimbursed, and Affordable, VASCEPA Expected to Benefit from Increased Attention to Patients with Severely Elevated Triglycerides

DUBLIN, Ireland and BRIDGEWATER, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, applauds the recent FDA approval of injectable apolipoprotein C-III (APOC3) therapies for the treatment of severe hypertriglyceridemia (sHTG), defined as triglycerides (TG) greater than or equal to 500 mg/dL.ⁱ These injectable therapies represent meaningful progress for patients at high risk for serious, sometimes life-threatening diseases associated with sHTG, including acute

Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape

Tue, 30 Jun 2026 16:15:00 -0400

Clinically Validated, Increasingly Prescribed, Widely Reimbursed, and Affordable, VASCEPA Expected to Benefit from Increased Attention to Patients with Severely Elevated Triglycerides

U.S. Supreme Court rules in favor of generic drugmaker Hikma in 'skinny label' patent dispute over Amarin heart drug vascepa

Thu, 04 Jun 2026 10:02:27 -0400

U.S. Supreme Court rules in favor of generic drugmaker Hikma in 'skinny label' patent dispute over Amarin heart drug vascepa

Thu, 04 Jun 2026 10:02:27 -0400

U.S. Supreme Court rules in favor of generic drugmaker Hikma in 'skinny label' patent dispute over Amarin heart drug vascepa

Amarin presents analysis on risk-weighted apoB for cardiovascular patients

Wed, 27 May 2026 08:01:23 -0400

Amarin Corporation (NASDAQ: AMRN) announced results from a post hoc analysis of the REDUCE-IT trial presented at the European Atherosclerosis Society Congress 2026. The analysis examined risk-weighted apolipoprotein B as a potential biomarker for identifying cardiovascular risk in statin-treated patients with elevated triglycerides.

The study evaluated 3,485 participants from the REDUCE-IT placebo arm over a median follow-up of 4.9 years. Risk-weighted apoB levels were calculated to be approximately 30% higher than measured apoB. The analysis found that risk-weighted apoB demonstrated superior risk prediction for cardiovascular outcomes compared with LDL-C, non-HDL-C, and apoB in this patient population.

Risk-weighted apoB incorporates differential weights for

Amarin presents analysis on risk-weighted apoB for cardiovascular patients

Wed, 27 May 2026 08:01:23 -0400

Risk-weighted apoB incorporates differential weights for

New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated

Wed, 27 May 2026 08:00:00 -0400

DUBLIN and BRIDGEWATER, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (Amarin), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today announced new data from a post hoc analysis of the REDUCE-IT® trial presented at the European Atherosclerosis Society (EAS) Congress 2026 in Athens, Greece.

The analysis, conducted in the REDUCE-IT placebo arm, evaluated risk-weighted apolipoprotein B (RW-apoB), an integrated metric designed to reflect the relative atherogenicity of apoB-containing lipoproteins. Among statin-treated patients with elevated triglycerides (TG) , RW-apoB was found to more effectively identify individuals at increased residual

New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated

Wed, 27 May 2026 08:00:00 -0400

New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated

Wed, 27 May 2026 08:00:00 -0400

New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated

Wed, 27 May 2026 08:00:00 -0400

New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated

Wed, 27 May 2026 08:00:00 -0400